Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Aprea Therapeutics (NASDAQ:APRE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.
Analyst Ratings
This is a summary of current recommendations and price targets for Unicycive Therapeutics and Aprea Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
| Aprea Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Unicycive Therapeutics presently has a consensus target price of $5.13, suggesting a potential upside of 1,129.61%. Aprea Therapeutics has a consensus target price of $15.50, suggesting a potential upside of 463.64%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Unicycive Therapeutics is more favorable than Aprea Therapeutics.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | $680,000.00 | 23.05 | -$30.54 million | ($1.19) | -0.35 |
| Aprea Therapeutics | $580,000.00 | 25.75 | -$14.29 million | ($3.32) | -0.83 |
Aprea Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Unicycive Therapeutics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
Profitability
This table compares Unicycive Therapeutics and Aprea Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | N/A | -34.98% |
| Aprea Therapeutics | -1,012.37% | -56.38% | -46.35% |
Insider & Institutional Ownership
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 12.8% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Unicycive Therapeutics beats Aprea Therapeutics on 13 of the 15 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
